Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.
作者信息
Lavery Jessica A, Panageas Katherine S
机构信息
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
J Hosp Manag Health Policy. 2019 Apr;3. doi: 10.21037/jhmhp.2019.04.01. Epub 2019 Apr 9.
Abstract
摘要
相似文献
1
Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival.
J Hosp Manag Health Policy. 2019 Apr;3. doi: 10.21037/jhmhp.2019.04.01. Epub 2019 Apr 9.
2
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis.
Ther Innov Regul Sci. 2013 Mar;47(2):167-174. doi: 10.1177/0092861512459733.
3
Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
Eur J Cancer. 2011 Aug;47(12):1772-8. doi: 10.1016/j.ejca.2011.02.013. Epub 2011 Mar 21.
4
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28.
5
Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.
Stat Med. 2016 Sep 30;35(22):3923-32. doi: 10.1002/sim.6963. Epub 2016 Apr 18.
6
Model free audit methodology for bias evaluation of tumour progression in oncology.
Pharm Stat. 2015 Nov-Dec;14(6):455-63. doi: 10.1002/pst.1707. Epub 2015 Oct 5.
7
Evaluation of discordance measures in oncology studies with blinded independent central review of progression-free survival using an observational error model.
J Biopharm Stat. 2013;23(5):971-85. doi: 10.1080/10543406.2013.813516.
8
Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials.
Clin Cancer Res. 2013 May 15;19(10):2637-45. doi: 10.1158/1078-0432.CCR-12-3364. Epub 2013 Mar 26.
9
Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection.
Cancer Imaging. 2018 Dec 11;18(1):50. doi: 10.1186/s40644-018-0186-0.
10
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.
引用本文的文献
1
Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.
Oncologist. 2024 Aug 5;29(8):e1073-e1081. doi: 10.1093/oncolo/oyad012.
本文引用的文献
1
Exaggeration of PFS by blinded, independent, central review (BICR).
Ann Oncol. 2019 Feb 1;30(2):332-338. doi: 10.1093/annonc/mdy514.
2
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis.
Ther Innov Regul Sci. 2013 Mar;47(2):167-174. doi: 10.1177/0092861512459733.
3
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.
BMJ Open. 2018 Sep 10;8(9):e017240. doi: 10.1136/bmjopen-2017-017240.
4
Bias in progression-free survival analysis due to intermittent assessment of progression.
Stat Med. 2015 Oct 30;34(24):3181-93. doi: 10.1002/sim.6529. Epub 2015 May 24.
5
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
Cancer. 2012 Nov 1;118(21):5358-65. doi: 10.1002/cncr.27528. Epub 2012 Mar 20.
6
Censoring in survival analysis: Potential for bias.
Perspect Clin Res. 2012 Jan;3(1):40. doi: 10.4103/2229-3485.92307.
7
Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.
Curr Oncol. 2011 Oct;18 Suppl 2(Suppl 2):S5-S10. doi: 10.3747/co.v18is2.941.
8
Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.
Eur J Cancer. 2011 Aug;47(12):1772-8. doi: 10.1016/j.ejca.2011.02.013. Epub 2011 Mar 21.
9
Blinded independent central review of the progression-free survival endpoint.
Oncologist. 2010;15(5):492-5. doi: 10.1634/theoncologist.2009-0261.
10
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.
Zotero 插件